ARHGEF2 and neoplasm: In addition, the significantly larger tumors observed in ansamitocin-P3-treated GEF-H1−/− compared with WT mice suggests that GEF-H1 regulates the anti-tumor efficacy of ansamitocin-P3 (Figure 6H).